Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aspira Women's Health Inc.AWH · Entity 7871 | Interim CEO | December 31, 2024 | January 29, 2025 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | September 23, 2026 | September 25, 2026 |
| Organon & Co.OGN · Entity 4115 | Head of Research & Development | May 04, 2023 | May 08, 2023 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aspira Women's Health Inc.
Report date December 31, 2024 · Filed January 29, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,644 |
Last balance in matching sequence
After 2025-01-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-12-31 · Exercise / conversion · Acquired 20,000 · Balance 20,000 F1: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on October 28, 2024. Row 2 · 2025-01-08 · Tax withholding · Disposed 6,356 · Balance 13,644 F2: This line reflects the tax withholding on the vesting of RSUs that vested on December 31, 2024. F5: This report is being filed to correct the number of shares held after tax withholding on the vesting of RSUs that vested on December 31, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-12-31 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2024-12-31 · Exercise / conversion · Acquired 20,000 · Balance 0 F3: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F4: On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on October 28, 2024.
F2: This line reflects the tax withholding on the vesting of RSUs that vested on December 31, 2024.
F3: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.
F4: On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4.
F5: This report is being filed to correct the number of shares held after tax withholding on the vesting of RSUs that vested on December 31, 2024.
Gossamer Bio, Inc.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.99 · Expires 2036-09-22 | Direct | 10,000 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 10,000 · Balance 10,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Organon & Co.
Report date May 04, 2023 · Filed May 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,599 |
Ending reported balance
After 2023-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-04 · Exercise / conversion · Acquired 4,984 · Balance 30,767 F1: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Row 2 · 2023-05-04 · Tax withholding · Disposed 2,168 · Balance 28,599 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 4,984 |
Reported balance
After 2023-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-04 · Exercise / conversion · Disposed 4,984 · Balance 4,984 F1: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024.
Spyre Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.51 · Expires 2036-05-27 | Direct | 8,026 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 8,026 · Balance 8,026 F1: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 44,503 | $0.00 Strike: $36.91 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 12 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,503 Underlying: Common Stock · 44,503 shares Expires 2030-04-30 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F11 · derivative.exercise_date: 14,834 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 41,588 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 11 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,588 Underlying: Common Stock · 41,588 shares Expires 2029-05-02 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F10 · derivative.exercise_date: 27,724 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 53,919 | $0.00 Strike: $27.44 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 10 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,919 Underlying: Common Stock · 53,919 shares Expires 2028-05-03 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 63,054 | $0.00 Strike: $30.40 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 9 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,054 Underlying: Common Stock · 63,054 shares Expires 2027-05-04 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 48,931 | $0.00 Strike: $25.98 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 8 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,931 Underlying: Common Stock · 48,931 shares Expires 2026-05-09 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 19,828 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 7 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,828 Underlying: Common Stock · 19,828 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 7,975 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 6 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,975 Underlying: Common Stock · 7,975 shares Expires 2022-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 10,170 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 5 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,170 Underlying: Common Stock · 10,170 shares Expires 2021-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 14,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 4 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,957 Underlying: Common Stock · 14,957 shares Expires 2024-05-04 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 3,795 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,795 Underlying: Common Stock · 3,795 shares Expires 2023-05-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 1,842 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,842 Underlying: Common Stock · 1,842 shares Expires 2022-05-03 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.